
Protagonist Therapeutics (PTGX) P/E Ratio
P/E Ratio as of Dec 3, 2025: 135.89
Average131.34
Median133.83
Minimum107.35
Maximum142.20
135.89
29.31 (27.50%)past month
The P/E ratio for Protagonist Therapeutics (PTGX) is 135.89 as of Dec 3, 2025. This represents a increase of 141.07% compared to its 12-month average P/E ratio of 56.37. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Protagonist Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Protagonist Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Protagonist Therapeutics to industry peers.
Protagonist Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Protagonist Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Protagonist Therapeutics to industry peers.
Protagonist Therapeutics (PTGX) P/E Ratio Insights
See Protagonist Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares
Protagonist Therapeutics (PTGX) P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Dec 1, 2025 | $85.64 | 135.21 |
| Nov 3, 2025 | $75.95 | 106.58 |
| Oct 1, 2025 | $64.00 | 89.81 |
| Sep 2, 2025 | $58.85 | 82.58 |
| Aug 1, 2025 | $53.83 | 70.76 |
| Jul 1, 2025 | $50.21 | 66.00 |
| Jun 2, 2025 | $50.15 | 65.93 |
| May 1, 2025 | $44.99 | 10.70 |
| Apr 1, 2025 | $46.88 | 11.15 |
| Mar 3, 2025 | $38.50 | 9.15 |
| Feb 3, 2025 | $37.20 | 13.96 |
| Jan 2, 2025 | $38.98 | 14.62 |
Protagonist Therapeutics (PTGX) End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | 135.89 | +838.47% |
| 2024 | 14.48 | -265.11% |
| 2023 | -8.77 | +114.43% |
| 2022 | -4.09 | -67.69% |
| 2021 | -12.66 | +25.72% |
| 2020 | -10.07 | — |
FAQs About Protagonist Therapeutics (PTGX) P/E ratio
The latest P/E ratio of Protagonist Therapeutics (PTGX) is 135.89, as of Dec 3, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Protagonist Therapeutics’s last 12-month average P/E ratio is 56.37, compared to its current P/E ratio of 135.89. This reflects a increase of 141.07%.
Protagonist Therapeutics’s current P/E ratio of 135.89 is higher than its last 12-month average P/E of 56.37. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Protagonist Therapeutics’s average P/E ratio over the last 3 years is 18.46. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Protagonist Therapeutics’s average P/E ratio over the last 5 years is 6.7. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.